First ever head-to-head analysis compares overall survival outcomes of ERLEADA® versus darolutamide Retrospective study reinforces real-world efficacy of ERLEADA® for patients with mCSPC HORSHAM, PA – Johnson & Johnson announced new real… Read More
Future-ready hospital campus represents an investment of more than $500 million to expand emergency, inpatient, and surgical care in western Broward County. Turner Construction Company joined Baptist Health and community… Read More
NPK signs MOU with Canadian precision healthcare company ‘Molecular You’, the collaboration displaying momentum in precision healthcare and preventive medicine based on microbial metabolites. NPK Co., Ltd., a manufacturer of… Read More
VANCOUVER, B.C. — ME Therapeutics Holdings Inc , a publicly listed biotechnology company working on novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased… Read More
AMPLITUDE is the first clinical trial to evaluate potential therapies for patients with mHSPC and known HRR gene alterations, with positive results supporting the niraparib-based combination regimen as a new… Read More
